India’s drug regulator clears Meril’s MyvalFebruary 4, 2019
The Central Drugs Standard Control Organization (CDSCO), India’s top drug regulator, has granted approval for Myval-Transcatheter Aortic Heart Valve Replacement (TAVR) technology from Meril Life Sciences.
The device is the first indigenously developed and manufactured TAVR technology.
Headquartered in Vapi, Gujarat, the company received approval for the Myval TAVR technology on the basis of successful results from clinical study done in India.
With the launch, Meril Life will become the first Indian company to commercially make this therapy available in the country. The company will soon bring the next generation treatment modality to thousands of patients across the country and globally, Meril said in a press release.